m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03853)
Name
OS2966
Status
Phase 1
TTD Drug ID
DB8MR6
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Integrin beta-1 (ITGB1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Integrin beta-1 (ITGB1) is a therapeutic target for OS2966. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of OS2966 through regulating the expression of Integrin beta-1 (ITGB1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Integrin beta-1 (ITGB1) is a therapeutic target for OS2966. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OS2966 through regulating the expression of Integrin beta-1 (ITGB1). [2], [3]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Integrin beta-1 (ITGB1) is a therapeutic target for OS2966. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of OS2966 through regulating the expression of Integrin beta-1 (ITGB1). [2], [4]
References
Ref 1 N(6)-Methyladenosine RNA Demethylase FTO Promotes Gastric Cancer Metastasis by Down-Regulating the m6A Methylation of ITGB1. Front Oncol. 2021 Jul 1;11:681280. doi: 10.3389/fonc.2021.681280. eCollection 2021.
Ref 2 Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013 Aug;1(2):134-43. doi: 10.1158/2326-6066.CIR-13-0007. Epub 2013 May 20.
Ref 3 METTL3 enhances cell adhesion through stabilizing integrin Beta1 mRNA via an m6A-HuR-dependent mechanism in prostatic carcinoma. Am J Cancer Res. 2020 Mar 1;10(3):1012-1025. eCollection 2020.
Ref 4 KAT1 triggers YTHDF2-mediated ITGB1 mRNA instability to alleviate the progression of diabetic retinopathy. Pharmacol Res. 2021 Aug;170:105713. doi: 10.1016/j.phrs.2021.105713. Epub 2021 Jun 5.